Biologic drugs in Gastroenterology       

FOI REFERENCE: 24400    FOI DATE: 3^rd October 2024      

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira                       13
• Adalimumab Biosimilar                      162
• Etrasimod                                           0
• Filgotinib                                             *
• Golimumab                                         *
• Infliximab – Remicade                        0
• Infliximab Biosimilar                           321
• Mirikizumab                                        0
• Ozanimod                                           0
• Risankizumab                                     9
• Tofacitinib                                           15
• Upadacitinib                                        28
• Ustekinumab                                       99
• Ustekinumab Biosimilar                      0
• Vedolizumab                                       124

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018